End-Stage Renal Disease (ESRD) Market Summary

• The End-Stage Renal Disease Market Size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• Several pharmaceutical and biotech companies are actively engaged in developing therapies for End-Stage Renal Disease, aiming to improve outcomes and quality of life for affected patients globally. Key End-Stage Renal Disease Companies involved in the drug development - Medtronic PLC, B. Braun SE, Asahi Kasei Medical Co. Ltd, Cantel Medical (STERIS), Nikkiso Co. Ltd, Nipro Corporation, Fresenius SE & Co. KGaA, and others.

Request for unlocking the Sample Page of the "End-Stage Renal Disease Market Insights"

Key Factors Driving the Growth of the End-Stage Renal Disease Market

• Rising prevalence of chronic kidney disease (CKD) and diabetes: The growing global burden of Chronic Kidney Disease and diabetes, major risk factors for ESRD, is increasing the number of patients progressing to end-stage renal failure, driving demand for treatment and dialysis services.
• Advancements in dialysis technologies and treatment options: Innovations in hemodialysis, peritoneal dialysis, and kidney transplant procedures, along with new pharmacological therapies for managing complications, are improving patient outcomes and expanding market adoption.
• Increasing awareness and early diagnosis: Improved screening programs and awareness campaigns for CKD and ESRD promote early intervention, timely dialysis initiation, and better disease management, fueling market growth.
• Favorable healthcare policies and reimbursement support: Government initiatives, insurance coverage, and reimbursement programs for dialysis and ESRD treatments enhance patient access, encouraging broader utilization of therapies.
• Growing geriatric population and longer life expectancy: An aging population with higher susceptibility to kidney dysfunction increases the prevalence of ESRD, driving demand for dialysis services, transplantation, and supportive therapies.

DelveInsight's "End-Stage Renal Disease Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the End-Stage Renal Disease, historical and forecasted epidemiology as well as the End-Stage Renal Disease therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The End-Stage Renal Disease market report provides current treatment practices, emerging drugs, End-Stage Renal Disease market share of the individual therapies, current and forecasted End-Stage Renal Disease market Size from 2020 to 2034 segmented by seven major markets. The Report also covers current End-Stage Renal Disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the End-Stage Renal Disease market.

End-Stage Renal Disease Understanding

The DelveInsight’s End-Stage Renal Disease market report gives a thorough understanding of the End-Stage Renal Disease by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

End-Stage Renal Disease Overview

End-stage renal disease (ESRD) is the final stage of chronic kidney disease, where the kidneys lose nearly all their ability to function. Patients with ESRD require renal replacement therapy, such as hemodialysis, peritoneal dialysis, or kidney transplantation, to survive. The condition often results from diabetes, hypertension, or other chronic kidney disorders, and can lead to severe complications affecting the cardiovascular system, bone health, and overall quality of life. Early detection and management of underlying conditions are crucial to slow disease progression and improve outcomes.

End-Stage Renal Disease Diagnosis

Diagnosis of end-stage renal disease (ESRD) involves assessing kidney function through blood tests (measuring serum creatinine and estimating glomerular filtration rate, eGFR) and urine tests to detect proteinuria or other abnormalities. Imaging studies, such as ultrasound devices or CT scans, may be used to evaluate kidney size and structure. ESRD is typically diagnosed when kidney function declines to less than 15% of normal, indicating the need for renal replacement therapy like dialysis or transplantation. Regular monitoring of patients with chronic kidney disease is essential for early detection and timely intervention.

End-Stage Renal Disease Treatment

It covers the details of conventional and current medical therapies available in the End-Stage Renal Disease market for the treatment of the condition. It also provides End-Stage Renal Disease treatment algorithms and guidelines in the United States, Europe, and Japan. End-Stage Renal Disease clinical trials focus on innovative therapies, dialysis improvements, transplant outcomes, and disease progression, aiming to enhance patient survival, quality of life, and treatment efficacy.

End-Stage Renal Disease Epidemiology 

The End-Stage Renal Disease epidemiology section provides insights about the historical and current End-Stage Renal Disease patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the End-Stage Renal Disease market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings of the End-Stage Renal Disease Epidemiology Report

The End-Stage Renal Disease epidemiology covered in the report provides historical as well as forecasted End-Stage Renal Disease epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

• According to the Centers for Disease Control and Prevention (2022), as of December 31, 2018, ~0.7 million patients (785,883) were being treated for end-stage renal disease (End-Stage Renal Disease) in the United States, giving a point prevalence of 2,382 per million population; the prevalence of dialysis treatment was 1,685 per million, whereas the prevalence of functioning kidney transplant was 696 per million.
• Gender differences have been documented in the field of nephrology. Women seem to be somewhat protected from developing End-Stage Renal Disease. A nationwide survey of End-Stage Renal Disease by the Japanese Society for Dialysis Therapy revealed a higher prevalence in men than in women. Further, the mean age at the start of dialysis is lower in men than in women.

Country Wise- End-Stage Renal Disease Epidemiology

The epidemiology segment also provides the End-Stage Renal Disease epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

End-Stage Renal Disease Epidemiology Segmentation

• Total Diagnosed Prevalent Cases of End Stage Renal Disease in the 7MM
• Gender-specific Diagnosed Prevalent Cases of End Stage Renal Disease in the 7MM
• Cause-specific Diagnosed Prevalent Cases of  End Stage Renal Disease in the 7MM
• Treated Cases of End Stage Renal Disease in the 7MM

End-Stage Renal Disease Drug Analysis

The End-Stage Renal Disease drug chapter segment encloses the detailed analysis of End-Stage Renal Disease marketed drugs and late-stage (Phase-III and Phase-II) End-Stage Renal Disease pipeline drugs. It also helps to understand the End-Stage Renal Disease clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. The End-Stage Renal Disease (End-Stage Renal Disease) drugs market is expanding due to rising End-Stage Renal Disease prevalence, technological advancements, and increasing demand for effective dialysis, transplant therapies, and supportive pharmaceutical treatments worldwide.

End-Stage Renal Disease Marketed Drugs

The end-stage renal disease (ESRD) market includes drugs primarily used to manage complications associated with kidney failure and dialysis. Key marketed therapies address anemia (erythropoiesis-stimulating agents and iron supplements), mineral and bone disorders (phosphate binders, vitamin D analogs, and calcimimetics), and cardiovascular risks. While dialysis and transplantation remain the core treatment approaches, these supportive medications play a critical role in improving patient outcomes, reducing complications, and enhancing quality of life in ESRD patients.

End-Stage Renal Disease Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for End-Stage Renal Disease treatment.

• AB002: Aronora

AB002 (E-WE thrombin), is a first-in-class protein C activator enzyme. AB002 has been designed to act in part by increasing the surface concentration of the anticoagulant, profibrinolytic, and cytoprotective enzyme, endogenous activated protein C (APC), at the site of developing blood clots via targeted cellular delivery. This unique mechanism of action allows AB002 to target cell-rich pathological blood clots (thrombi) without disabling vital hemostasis.

• MK-2060: Merck 

MK-2060 is a novel inhibitor of Factor XI being investigated for the prevention of thrombosis in patients with end-stage renal disease (End-Stage Renal Disease). MK-2060, administered intravenously, is designed to work through a dual mechanism of action both blocking the activation of Factor XI as well as the downstream activity of the activated protein.

End-Stage Renal Disease Market Outlook

The End-Stage Renal Disease market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted End-Stage Renal Disease market trends by analyzing the impact of current End-Stage Renal Disease therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of End-Stage Renal Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated End-Stage Renal Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the End-Stage Renal Disease market in 7MM is expected to witness a major change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the End-Stage Renal Disease market in 7MM.

The United States End-Stage Renal Disease Market Outlook

This section provides the total End-Stage Renal Disease market size and market size by therapies in the United States.

EU-5 Countries End-Stage Renal Disease Market Outlook

The total End-Stage Renal Disease market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan End-Stage Renal Disease Market Outlook

The total End-Stage Renal Disease market size and market size by therapies in Japan is also mentioned.

End-Stage Renal Disease (ESRD) Competitive Landscape

The End-Stage Renal Disease (ESRD) competitive landscape is shaped by a mix of large dialysis service providers, pharmaceutical companies, and medical device manufacturers. The market is highly consolidated, with a few dominant players controlling a significant share of global dialysis services, particularly hemodialysis and peritoneal dialysis. These companies compete on the basis of treatment quality, geographic reach, integrated care models, and cost efficiency.

Pharmaceutical players contribute by developing drugs that manage ESRD-associated complications such as anemia, mineral and bone disorders, and cardiovascular risks. Meanwhile, device manufacturers focus on innovations in dialysis machines, dialyzers, and home-based dialysis systems to improve patient convenience and outcomes.

Competition is intensifying due to rising ESRD prevalence, increasing demand for home dialysis, and supportive reimbursement policies in developed markets. Strategic collaborations, acquisitions, and investments in digital health and value-based care models are common strategies adopted by key players. Additionally, emerging therapies, wearable dialysis technologies, and regenerative medicine approaches are expected to gradually reshape the ESRD landscape, creating new competitive opportunities beyond traditional dialysis-centric care.

Key End-Stage Renal Disease Companies

The Key End-Stage Renal Disease companies actively involved in the End-Stage Renal Disease treatment landscape include - 

• Medtronic PLC
• B. Braun SE
• Asahi Kasei Medical Co. Ltd
• Cantel Medical (STERIS)
• Nikkiso Co. Ltd
• Nipro Corporation
• Fresenius SE & Co. KGaA
• Baxter International Inc
• Becton, Dickinson and Company, and others

End-Stage Renal Disease Drugs Uptake

This section focuses on the rate of uptake of the potential End-Stage Renal Disease drugs recently launched in the End-Stage Renal Disease market or expected to get launched in the market during the study period 2020-2034. The analysis covers End-Stage Renal Disease market uptake by drugs; patient uptake by therapies; and sales of each drug.   

End-Stage Renal Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of End-Stage Renal Disease market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

End-Stage Renal Disease Clinical Trial Activities

The End-Stage Renal Disease report provides insights into different End-Stage Renal Disease clinical trials within in Phase II, and Phase III stage. It also analyses End-Stage Renal Disease key players involved in developing targeted therapeutics.

End-Stage Renal Disease Pipeline Development Activities

The End-Stage Renal Disease pipeline report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for End-Stage Renal Disease emerging therapies.

End-Stage Renal Disease Market Reimbursement Scenario

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Latest KOL- Views on End-Stage Renal Disease Market Report

To keep up with current End-Stage Renal Disease market trends, we take KOLs and SMEs ' opinion working in the End-Stage Renal Disease domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or End-Stage Renal Disease market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

End-Stage Renal Disease Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the End-Stage Renal Disease Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the End-Stage Renal Disease Market Report

• The report covers the descriptive overview of End-Stage Renal Disease, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the End-Stage Renal Disease epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for End-Stage Renal Disease is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the End-Stage Renal Disease market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global End-Stage Renal Disease market

End-Stage Renal Disease Market Report Highlights

• In the coming years, the End-Stage Renal Disease market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The End-Stage Renal Disease companies and academics are working to assess challenges and seek opportunities that could influence End-Stage Renal Disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for End-Stage Renal Disease. The launch of emerging therapies will significantly impact the End-Stage Renal Disease market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for End-Stage Renal Disease
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

End-Stage Renal Disease Market Report Insights

• End-Stage Renal Disease Patient Population
• End-Stage Renal Disease Therapeutic Approaches
• End-Stage Renal Disease Pipeline Analysis
• End-Stage Renal Disease Market Size and Trends
• End-Stage Renal Disease Market Opportunities
• Impact of upcoming End-Stage Renal Disease Therapies

End-Stage Renal Disease Market Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• End-Stage Renal Disease Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• End-Stage Renal Disease Drugs Uptake

End-Stage Renal Disease Market Report Assessment

• Current End-Stage Renal Disease Treatment Practices
• End-Stage Renal Disease Unmet Needs
• End-Stage Renal Disease Pipeline Product Profiles
• End-Stage Renal Disease Market Attractiveness
• End-Stage Renal Disease Market Drivers
• End-Stage Renal Disease Market Barriers

Key Questions Answered In The End-Stage Renal Disease Market Report:

End-Stage Renal Disease Market Insights:

• What was the End-Stage Renal Disease drug class share (%) distribution in 2020 and how it would look like in 2034?
• What would be the End-Stage Renal Disease total market size as well as market size by therapies across the 7MM during the forecast period (2020-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest End-Stage Renal Disease market size during the forecast period (2020-2034)?
• At what CAGR, the End-Stage Renal Disease market is expected to grow by 7MM during the forecast period (2020-2034)?
• What would be the End-Stage Renal Disease market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the End-Stage Renal Disease market growth till 2034, and what will be the resultant market Size in the year 2034?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

End-Stage Renal Disease Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the End-Stage Renal Disease?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical End-Stage Renal Disease patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of End-Stage Renal Disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to End-Stage Renal Disease?
• Out of all 7MM countries, which country would have the highest prevalent population of End-Stage Renal Disease during the forecast period (2020-2034)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2020-2034)?

Current End-Stage Renal Disease Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the End-Stage Renal Disease treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of End-Stage Renal Disease in the USA, Europe, and Japan?
• What are the End-Stage Renal Disease marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many End-Stage Renal Disease companies are developing therapies for the treatment of End-Stage Renal Disease?
• How many therapies are in-development by each company for End-Stage Renal Disease treatment?
• How many are emerging therapies in mid-stage, and late stage of development for End-Stage Renal Disease treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the End-Stage Renal Disease therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for End-Stage Renal Disease and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for End-Stage Renal Disease?
• What are the global historical and forecasted market of End-Stage Renal Disease?

Reasons to buy End-Stage Renal Disease Market Forecast Report

• The report will help in developing business strategies by understanding trends shaping and driving the End-Stage Renal Disease market
• To understand the future market competition in the End-Stage Renal Disease market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for End-Stage Renal Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for End-Stage Renal Disease market
• To understand the future market competition in the End-Stage Renal Disease market